Last reviewed · How we verify
Albuterol/salbutamol MDIs
Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation.
Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation. Used for Acute bronchospasm relief in asthma, Chronic obstructive pulmonary disease (COPD) symptom relief, Exercise-induced bronchoconstriction prevention.
At a glance
| Generic name | Albuterol/salbutamol MDIs |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Short-acting beta-2 agonist (SABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and airway dilation, providing rapid relief of bronchoconstriction. The metered-dose inhaler (MDI) formulation delivers the drug directly to the lungs for quick onset of action.
Approved indications
- Acute bronchospasm relief in asthma
- Chronic obstructive pulmonary disease (COPD) symptom relief
- Exercise-induced bronchoconstriction prevention
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma (PHASE3)
- Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma (NA)
- Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma (PHASE4)
- Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients (PHASE2)
- Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma (PHASE3)
- Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients (PHASE4)
- Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma (PHASE3)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albuterol/salbutamol MDIs CI brief — competitive landscape report
- Albuterol/salbutamol MDIs updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI